sfam_photo / Shutterstock.com
Healthcare company Fresenius Kabi has targeted Sagent Pharmaceuticals in a patent infringement lawsuit centring on generic versions of Naropin.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Fresenius Kabi, patent, patent infringement, ANDA, Sagent Pharmaceuticals, generics,